Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

Objectives This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. Methods Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) ( nab -paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly ( P < 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a...